Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Chronic obstructive pulmonary disease upper airway microbiome is associated with select clinical characteristics.

Pragman AA, Knutson KA, Gould TJ, Hodgson SW, Isaacson RE, Reilly CS, Wendt CH.

PLoS One. 2019 Jul 23;14(7):e0219962. doi: 10.1371/journal.pone.0219962. eCollection 2019.

2.

Chronic obstructive pulmonary disease upper airway microbiota alpha diversity is associated with exacerbation phenotype: a case-control observational study.

Pragman AA, Knutson KA, Gould TJ, Isaacson RE, Reilly CS, Wendt CH.

Respir Res. 2019 Jun 7;20(1):114. doi: 10.1186/s12931-019-1080-4.

3.

The relationship between oral health and COPD exacerbations.

Baldomero AK, Siddiqui M, Lo CY, Petersen A, Pragman AA, Connett JE, Kunisaki KM, Wendt CH.

Int J Chron Obstruct Pulmon Dis. 2019 Apr 23;14:881-892. doi: 10.2147/COPD.S194991. eCollection 2019.

4.

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.

Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA, Vestbo J, Yates JC, Niewoehner DE; SUMMIT Investigators.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):51-57. doi: 10.1164/rccm.201711-2239OC.

PMID:
29442524
5.

The lung tissue microbiota of mild and moderate chronic obstructive pulmonary disease.

Pragman AA, Lyu T, Baller JA, Gould TJ, Kelly RF, Reilly CS, Isaacson RE, Wendt CH.

Microbiome. 2018 Jan 9;6(1):7. doi: 10.1186/s40168-017-0381-4.

6.
7.

Chronic obstructive pulmonary disease lung microbiota diversity may be mediated by age or inhaled corticosteroid use.

Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE.

J Clin Microbiol. 2015 Mar;53(3):1050. doi: 10.1128/JCM.03320-14. No abstract available.

8.

Longitudinal analysis of the lung microbiome in lung transplantation.

Borewicz K, Pragman AA, Kim HB, Hertz M, Wendt C, Isaacson RE.

FEMS Microbiol Lett. 2013 Feb;339(1):57-65. doi: 10.1111/1574-6968.12053. Epub 2012 Dec 20.

9.

The lung microbiome in moderate and severe chronic obstructive pulmonary disease.

Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE.

PLoS One. 2012;7(10):e47305. doi: 10.1371/journal.pone.0047305. Epub 2012 Oct 11.

10.

Infectious Disease Consultation for Staphylococcus aureus Bacteremia Improves Patient Management and Outcomes.

Pragman AA, Kuskowski MA, Abraham JM, Filice GA.

Infect Dis Clin Pract (Baltim Md). 2012 Jul 1;20(4):261-267.

11.

The staphylococcal respiratory response regulator SrrAB induces ica gene transcription and polysaccharide intercellular adhesin expression, protecting Staphylococcus aureus from neutrophil killing under anaerobic growth conditions.

Ulrich M, Bastian M, Cramton SE, Ziegler K, Pragman AA, Bragonzi A, Memmi G, Wolz C, Schlievert PM, Cheung A, Döring G.

Mol Microbiol. 2007 Sep;65(5):1276-87. Erratum in: Mol Microbiol. 2007 Oct;66(1):278.

12.

Sequence analysis of the Staphylococcus aureus srrAB loci reveals that truncation of srrA affects growth and virulence factor expression.

Pragman AA, Herron-Olson L, Case LC, Vetter SM, Henke EE, Kapur V, Schlievert PM.

J Bacteriol. 2007 Oct;189(20):7515-9. Epub 2007 Aug 10.

13.
14.

Virulence regulation in Staphylococcus aureus: the need for in vivo analysis of virulence factor regulation.

Pragman AA, Schlievert PM.

FEMS Immunol Med Microbiol. 2004 Oct 1;42(2):147-54. Review.

15.

Characterization of virulence factor regulation by SrrAB, a two-component system in Staphylococcus aureus.

Pragman AA, Yarwood JM, Tripp TJ, Schlievert PM.

J Bacteriol. 2004 Apr;186(8):2430-8.

16.

Functional characterization of streptococcal pyrogenic exotoxin J, a novel superantigen.

McCormick JK, Pragman AA, Stolpa JC, Leung DY, Schlievert PM.

Infect Immun. 2001 Mar;69(3):1381-8.

Supplemental Content

Loading ...
Support Center